Compare Cassava Sciences Inc (FLNA) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while iShares 10 20 Year Treasury Bond ETF trades at $98.33. The key difference: iShares 10 20 Year Treasury Bond ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TLH | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $105.36 |
52-Week Low | $1.09 | $97.13 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TLH trades at $98.405, up 0.2% on the day, with technical indicators showing a bearish trend overall despite oversold RSI readings. The stock faces resistance near $99 and support at $98. Recent dividends include H1-26 at $0.41 and H2-26 at $0.36, but key valuation and profitability ratios are unavailable, limiting fundamental clarity.
The outlook is cautious due to bearish technical signals and missing financial metrics. Risks include market volatility from geopolitical tensions and Federal Reserve uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
